Original ArticleOsimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
Under a Creative Commons license
open access
Key words
AURA3
osimertinib
epidermal growth factor receptor-tyrosine kinase inhibitor
non-small-cell lung cancer
overall survival
Cited by (0)
© 2020 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.